Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lexgenleucel-T (VRX496) / VIRxSYS Corp
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV	Active, not recruiting	2	60	US	VRX496-Modified Autologous T cells	VIRxSYS Corporation	HIV Infection	11/08	06/23
Rollover, NCT00622232: A Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial	Active, not recruiting	2	40	US	VRX496-transduced autologous CD4 T cells	VIRxSYS Corporation	HIV Infections	01/09	06/23